A randomized controlled trial of 108 people with HIV-associated lipohypertrophy found that weekly Ozempic treatment for 32 weeks reversed biological age by an average of 3.1 years.
The study used epigenetic clocks to measure biological aging, showing the most pronounced anti-aging effects in the inflammatory system and brain, where aging was delayed by almost 5 years.
Researchers believe the anti-aging effects stem from semaglutide's ability to improve fat distribution and reduce inflammation, both major drivers of cellular aging.